{"entity":{"id":"nct06637501","kind":"trial","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","aka":[],"tldr":"A phase 2 trial of Sonrotoclax and Zanubrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.","summary":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06637501 by BeOne Medicines, with 94 participants enrolled, started 2024-11-14 and due to reach its primary completion in 2026-11. Interventions recorded: Sonrotoclax and Zanubrutinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06637501","url":"https://clinicaltrials.gov/study/NCT06637501"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":["sonrotoclax","zanubrutinib"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06637501","phase":"2","setting":"A Multicenter, Open-Label, Phase 2 Study to Investigate the Efficacy and Safety of Sonrotoclax Combined With Zanubrutinib Compared With Zanubrutinib Monotherapy in Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"BeOne Medicines","enrolled":94,"outcomes":[]},"route":"/trials/nct06637501/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}